Marta López-Parra

发表

5‐lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor α–induced hepatocyte damage in hyperlipidemia‐prone ApoE‐null mice

V. Arroyo, C. Funk, J. Clària, 2010, Hepatology.

Inhibition of 5‐lipoxygenase‐activating protein abrogates experimental liver injury: role of Kupffer cells

V. Arroyo, J. Clària, R. Miquel, 2005, Journal of leukocyte biology.

Aspirin (ASA) regulates 5‐lipoxygenase activity and peroxisome proliferator‐activated receptor α‐mediated CINC‐1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA‐triggered 15‐epi‐LXA4

V. Arroyo, J. Clària, E. Titos, 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

5-Lipoxygenase Activating Protein Signals Adipose Tissue Inflammation and Lipid Dysfunction in Experimental Obesity

V. Arroyo, J. Clària, R. Deulofeu, 2010, The Journal of Immunology.

5-Lipoxygenase (5-LO) is Involved in Kupffer Cell Survival. Possible Role of 5-LO Products in the Pathogenesis of Liver Fibrosis.

N. Villamor, W. Jiménez, V. Arroyo, 2002, Comparative hepatology.

Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17Sâ•’hydroxyâ•’DHA

V. Arroyo, J. Rodés, K. Gronert, 2006 .

The Role of Inflammatory Mediators in Liver Failure

J. Clària, E. Titos, A. González-Périz, 2011 .

This information is current as Dysfunction in Experimental Obesity Adipose Tissue Inflammation and Lipid 5-Lipoxygenase Activating Protein Signals

V. Arroyo, J. Clària, R. Deulofeu, 2010 .

Enhancement of the Antioxidant Capacity of Thyme and Chestnut Honey by Addition of Bee Products

A. González-Porto, M. D. del Castillo, P. Morales, 2022, Foods.

The selective cyclooxygenase‐2 inhibitor SC‐236 reduces liver fibrosis by mechanisms involving non‐parenchymal cell apoptosis and PPARγ activation

J. Masferrer, V. Arroyo, J. Clària, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Cyclooxygenase‐1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites

J. Masferrer, W. Jiménez, V. Arroyo, 2002, British journal of pharmacology.

Renal effects of selective cyclooxygenase inhibition in experimental liver disease.

J. Masferrer, W. Jiménez, V. Arroyo, 2003, Advances in experimental medicine and biology.

Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase.

V. Arroyo, J. Lozano, J. Clària, 2010, Prostaglandins & other lipid mediators.

Comparative Protection against Liver Inflammation and Fibrosis by a Selective Cyclooxygenase-2 Inhibitor and a Nonredox-Type 5-Lipoxygenase Inhibitor

J. Masferrer, V. Arroyo, J. Clària, 2007, Journal of Pharmacology and Experimental Therapeutics.

Obesity‐induced insulin resistance and hepatic steatosis are alleviated by ω‐3 fatty acids: a role for resolvins and protectins

V. Arroyo, K. Gronert, J. Clària, 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Role for PPARγ in obesity‐induced hepatic steatosis as determined by hepatocyte‐ and macrophage‐specific conditional knockouts

Y. Barak, V. Arroyo, J. Clària, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.

J. Masferrer, V. Arroyo, J. Clària, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S‐hydroxy‐DHA

V. Arroyo, J. Rodés, K. Gronert, 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin.

J. Masferrer, W. Jiménez, V. Arroyo, 2005, Journal of hepatology.

Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites

G. Escolar, W. Jiménez, V. Arroyo, 2005, Hepatology.

Inhibition of 5‐lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis

N. Villamor, A. Carrió, W. Jiménez, 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols.

R. Bataller, J. Joven, V. Arroyo, 2009, American journal of physiology. Gastrointestinal and liver physiology.

Comparative Protection Against Liver Inflammation and Fibrosis by a Selective COX-2 Inhibitor and a Nonredox-type 5-LO Inhibitor

J. Masferrer, V. Arroyo, J. Clària, 2007 .

Gene expression profiling of renal dysfunction in rats with experimental cirrhosis.

V. Arroyo, J. Rodés, J. Clària, 2006, Journal of hepatology.

The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin.

J. Masferrer, W. Jiménez, V. Arroyo, 2005, Journal of hepatology.

80 ROLE FOR PPAR γ IN HEPATIC STEATOSIS AS DETERMINED BY HEPATOCYTE AND KUPFFER CELL-SPECIFIC CONDITIONAL KNOCKOUTS USING CRE RECOMBINASE

Y. Barak, V. Arroyo, J. Clària, 2010 .

Role for PPARγ in obesity‐induced hepatic steatosis as determined by hepatocyte‐ and macrophage‐specific conditional knockouts

Y. Barak, V. Arroyo, J. Clària, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

21 The selective cyclooxygenase-2 inhibitor SC-236 reduces experimental liver fibrosis by inactivating kupffer cells and acting as a peroxisome proliferator-activated receptor gamma ligand

J. Masferrer, V. Arroyo, J. Rodés, 2004 .